KS18, a Mcl-1 inhibitor, improves the effectiveness of bortezomib and overcomes resistance in refractory multiple myeloma by triggering intrinsic apoptosis

Omar S. Al‐Odat(Cooper Medical School of Rowan University), Manoj K. Pandey(Cooper Medical School of Rowan University)
Frontiers in Pharmacology
October 1, 2024
Cited by 4


Related Papers